Dedicated entirely to intellectual property, Finnegan Henderson Farabow Garrett & Dunner is one of the go-to law firms for litigation involving patents, trademarks, and copyrights. The firm remains a leader in handling disputes before the PTAB and has also maintained a significant reputation in the life sciences sphere. Finnegan’s offices span the East Coast, centering its power in the District of Columbia and Virginia area.
In DC, William Raich leads the biotechnology and pharmaceutical practice group and with a background in cellular and molecular biology, he is a top choice for patent-related cases. He and nationally recognized litigator
Charles Lipsey of the Reston, Virginia office are defending Sarepta Therapeutics in a lawsuit filed by Nippon Shinyaku which alleges that the client’s product Vyondys 53® infringes seven patents held by the plaintiff. Lipsey and Raich are currently active in fact discovery, and the trial is scheduled for May 2024.
The DC office also features James Monroe and
Paul Browning, both of whom are trial lawyers with an extensive record of cases before district and appellate courts nationwide. The duo was among the lead lawyers on the team representing Otsuka and Lundbeck in a series of ANDA cases filed in the District of Delaware. Eighteen generic drug manufacturers sought to create generic versions of the client’s drug Rexulti. Monroe, Browning, and the rest of the Finnegan team settled all eighteen cases favorably for the client, with the last settling on the eve of trial. The settlements protected the company’s multibillion-dollar drug franchise from infringing sales.
Robert Yoches splits his time between District of Columbia and Taipei, representing clients in both the US and China. Yoches represents Taiwan Semiconductor Manufacturing Company before the ITC in a Section 337 investigation. The plaintiff, Daedalus Prime, alleged that the client’s semiconductor chips infringe its patents.
Gerald Ivey is an established trial lawyer focusing on patent matters involving computer software and hardware. He is recognized for both his district court and PTAB appearances. Ivey recently defended Samsung in multiple
inter partes reviews in connection with patents concerning the display of multiple displays on smartphones.
On the trademark side, Douglas Rettew
remains the go-to litigator to handle cases nationwide. As first-chair trial lawyer, Rettew obtained a jury verdict in favor of Armadillo Distribution Enterprises and Concordia Investment Partners on his core affirmative defenses and on the plaintiff’s claims for damages. Gibson Brands had filed a lawsuit alleging serial infringement and counterfeiting of six registered trademarks against the clients, demanding over $7 million at trial. In addition to trial expertise and experience, Rettew is also an established name before the Trademark Trial and Appeal Board, representing multiple clients, including A&H Sportswear, in enforcement matters.
John Livingstone
of the Atlanta office also leads the charge litigating on behalf of clients in the life sciences industry. He represents Novartis Pharmaceuticals in a series of Hatch-Waxman Act patent cases filed in the District of Delaware against generic pharmaceutical companies looking to market versions of Kisqali, a treatment for certain metastatic breast cancers marketed by Novartis. The case has the potential to provide nine years of exclusivity. Separately, Livingstone defends Novartis Gene Therapies against patent infringement allegations asserted by Genzyme. The patents include recombinant adeno-associated virus sector technology, which Novartis uses in its breakthrough gene therapy Zolgensma. Livingstone is also an established litigator representing life sciences clients before the International Trade Commission. His recent victory for Ajinomoto involved a biotech investigation and subsequent evidentiary hearing at the ITC, which in its final determination found that the defendant, CheilJedang, infringed Ajinomoto’s patents, and therefore also issued a limited exclusion and cease-and-desist orders, barring the defendant from importing the infringing products. Fellow Atlanta partner and celebrated multidisciplinary intellectual property litigator Virginia Carron successfully defended
Nestlé in a business-critical patent infringement case in the Western District of New York. Steuben Foods sued the client alleging numerous claims related to five patents and claiming $500 million in damages. As lead partner on the case, Carron took a multifaceted defense strategy that challenged the validity of the patents before the PTAB and filed a series of motions for summary judgment in district court. She successfully narrowed the case to three patents and the district court further agreed with her claim construction position. Her aggressive strategy and briefing garnered a significant settlement agreement.
